Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2020 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2020.0409
Abstract: Importance Because of socioeconomic factors, many patients with advanced non-small cell lung cancer (NSCLC) do not receive immunotherapy in the first-line setting. It is unknown if the combination of immunotherapy with chemotherapy can provide clinical… read more here.
Keywords: pembrolizumab plus; advanced non; safety; plus docetaxel ... See more keywords
Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5757
Abstract: Pembrolizumab plus chemotherapy improved progression‐free survival (PFS) and overall survival (OS) compared with placebo plus chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple‐negative breast cancer with tumor programmed cell death ligand… read more here.
Keywords: plus chemotherapy; pembrolizumab plus; triple negative; negative breast ... See more keywords
Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-019-00820-6
Abstract: Background and ObjectivesIn first-line treatment of advanced renal cell carcinoma (aRCC), the KEYNOTE-426 study demonstrated a significant progression-free survival and overall survival for pembrolizumab plus axitinib in comparison with sunitinib. The objective of the current… read more here.
Keywords: pembrolizumab plus; cost; versus sunitinib; plus axitinib ... See more keywords
Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2021.1903321
Abstract: ABSTRACT Introduction: The dominant paradigm of sequential therapy of metastatic renal cell carcinoma (mRCC) with single agents has recently been challenged by improved outcomes obtained with combined regimens with immune checkpoint inhibitors. These combined regimens… read more here.
Keywords: renal cell; pembrolizumab plus; cell carcinoma; plus axitinib ... See more keywords
Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062
Sign Up to like & getrecommendations! Published in 2022 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyac188
Abstract: Abstract Objective First-line pembrolizumab with/without chemotherapy versus chemotherapy was evaluated in programmed death ligand 1 combined positive score ≥1, locally advanced/unresectable or metastatic gastric cancer/gastrooesophageal junction cancer in the KEYNOTE-062 study. We present results for… read more here.
Keywords: plus chemotherapy; pembrolizumab plus; chemotherapy versus; pembrolizumab ... See more keywords
Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Thoracic cancer"
DOI: 10.1111/1759-7714.14148
Abstract: OBJECTIVE Currently, several immune checkpoint inhibitors (ICIs) treatment for advanced non-small-cell lung cancer (NSCLC) have been investigated; their overall efficacy and safety remain unclear. METHODS We searched electronic databases such as PubMed, EMBASE, and the… read more here.
Keywords: chemotherapy; platinum based; pembrolizumab plus; plus platinum ... See more keywords
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE‐826
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Science"
DOI: 10.1111/cas.15479
Abstract: Pembrolizumab plus chemotherapy with or without bevacizumab demonstrated prolonged progression‐free survival (PFS) and overall survival (OS) versus chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer in the phase 3, randomized, double‐blind, placebo‐controlled KEYNOTE‐826… read more here.
Keywords: plus chemotherapy; patients persistent; pembrolizumab plus; placebo ... See more keywords
Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2022-003419
Abstract: It was with great enthusiasm that I read the recently published KEYNOTE 775. Pembrolizumab plus lenvatinib showed unprecedented results for advanced, recurrent, or metastatic endometrial cancer with improvements in overall survival, progressionfree survival, response rates,… read more here.
Keywords: endometrial cancer; plus lenvatinib; pembrolizumab plus; response ... See more keywords
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-0177
Abstract: Purpose: Combination therapy with reduced-dose programmed death 1 inhibitor plus standard-dose cytotoxic T-lymphocyte–associated antigen 4 inhibitor demonstrated efficacy, but substantial toxicity, in melanoma. We present long-term results of part 1B of KEYNOTE-029, which assessed safety… read more here.
Keywords: pembrolizumab plus; standard dose; reduced dose; dose pembrolizumab ... See more keywords
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-0793
Abstract: Purpose: Standard-dose pembrolizumab plus alternative-dose ipilimumab (1 mg/kg Q3W for 4 doses) were tolerable and had robust antitumor activity in advanced melanoma in cohort B of the phase 1 KEYNOTE-029 study. Cohort C evaluated standard-dose… read more here.
Keywords: pem200 ipi50; standard dose; ipilimumab; pembrolizumab plus ... See more keywords
Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-small cell lung cancer (NSCLC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e21717
Abstract: e21717Background: Pem+carbo+pac or nab-pac are approved first-line (1L) treatments for metastatic squamous NSCLC since 10/30/2018. Difference in real-world outcomes of these triplet combinations ar... read more here.
Keywords: outcomes pembrolizumab; real world; plus carboplatin; world outcomes ... See more keywords